Recent progress in the intranasal PLGA-based drug delivery for neurodegenerative diseases treatment.
Nasim Aghaei Delche, Reyhaneh Kheiri, Behnam Ghorbani Nejad, Mojgan Sheikhi, Malihe Sadat Razavi, Milad Rahimzadegan, Zahra Salmasi
Abstract
One of the most challenging problems of the current treatments of neurodegenerative diseases is related to the permeation and access of most therapeutic agents to the central nervous system (CNS), prevented by the blood-brain barrier (BBB). Recently, intranasal (IN) delivery has opened new prospects because it directly delivers drugs for neurological diseases into the brain via the olfactory route. Recently, PLGA-based nanocarriers have attracted a lot of interest for IN delivery of drugs. This review gathered clear and concise statements of the recent progress of the various developed PLGA-based nanocarriers for IN drug delivery in brain diseases including Alzheimer's, Parkinson's, brain tumors, ischemia, epilepsy, depression, and schizophrenia. Subsequently, future perspectives and challenges of PLGA-based IN administration are discussed briefly.